Class I on Presource kits shows how an infusion-set recall travels into convenience packs
FDA has put the Cardinal Health correction of Presource kits containing recalled BD Alaris infusion sets in its most serious recall class, a reminder that component recalls extend beyond the original product.
What happened
On 17 November 2026, FDA's MedWatch channel reported that the agency has classed Cardinal Health's correction of Presource convenience kits as Class I. The kits contain BD Alaris Pump Infusion Sets that have already been recalled. FDA describes Class I as its most serious recall type, and the kits are to be corrected before further use.
The entry is short. It confirms the classification, the product family (Presource kits), the recalled component (BD Alaris Pump Infusion Sets) and the instruction not to use kits until they are corrected. It does not say what defect triggered the original infusion-set recall, how many kits or lots are affected, or what the correction involves.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Sources this analysis is based on
- FDA classes Cardinal Health Presource kit correction as Class I over recalled BD Alaris infusion sets FDA MedWatch · Tue 17 Nov 2026
- CMS publishes Performance Year 2025 results for Medicare Shared Savings Program ACOs CMS · Tue 17 Nov 2026
- Medicare Shared Savings Program posts $2.5bn net savings in 2025, a ninth straight year CMS · Tue 17 Nov 2026
- AEMPS veterinary committees note 21 pharmacovigilance-driven authorisation changes and recall follow-up problems AEMPS · Tue 17 Nov 2026
- Commission grants marketing authorisation for Revolution Medicines' daraxonrasib product Rasonque European Commission (Union Register) · Mon 16 Nov 2026
- Pleasanton drug discovery firm Cyion to pay $528,336 over alleged False Claims Act grant violations HHS OIG · Mon 16 Nov 2026
Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.
Tablo power cord overheating alert shows how a simple instruction change becomes a PV control
FDA's early alert on Outset Medical's Tablo cords is a reminder that use-instruction updates depend on reporting, user follow-through and a clear view of what is still unknown.
Lantern Pharma's first TNBC site and Taiwan start meet a CEO exit and a $4.0M raise
Lantern Pharma reported trial milestones for LP-184 and LP-300 in the same release as a CEO resignation and a roughly $4.0M offering, a mix sponsors and CROs should read carefully.
EEA Decision 191/2026 extends six EU feed additive acts to EEA EFTA markets, minus Liechtenstein
The EEA Joint Committee has added six feed additive acts, including a monensin sodium renewal and a Duddingtonia flagrans approval, to Annex I. Market access teams should read it as a lesson in how EU rules reach EEA markets.